TY - JOUR
T1 - Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease
AU - Åkerud, P.
AU - Holm, P. C.
AU - Castelo-Branco, G.
AU - Sousa, K.
AU - Rodriguez, F. J.
AU - Arenas, E.
N1 - Funding Information:
We thank Dr. Evan Y. Snyder for supplying the c17.2 cells and for helpful discussions, Drs. Carlos Ibañez and Christopher Nosrat for providing the PSP cDNA and the GFRα4 probe, Dr. Jospeh Wagner for invaluable help in tissue culture procedures, Mrs. Lotta Skoog for secretarial help, and Mrs. Annika Ahlsen for additional assistance. Financial support was obtained from the European Commission, Swedish Foundation for Strategic Research, Swedish Royal Academy of Sciences, Swedish MRC, Karolinska Institute, Petrus and Augusta Hedlunds Foundation, Jeanssonska Foundation, and Kapten Arthur Eriksson Foundation. G.C.-B. was supported by the Portuguese Praxis XXI program of the Fundac¸ão para a Ciência e a Tecnologia. J.F.R. was supported by the Karolinska Institutet and the Marie Curie program of the European Union.
PY - 2002
Y1 - 2002
N2 - Persephin (PSP) is a neurotrophic factor of the GDNF family that has been found to promote the survival of multiple populations of neurons. In the present study we have examined: (1) the mechanism of action and the function of PSP on nigrostriatal dopamine neurons and (2) the therapeutic potential of PSP, delivered by neural stem cells (NSCs) in a model of Parkinson's disease. Interestingly we found that the prenatal ventral mesencephalon and the newborn striatum express high levels of PSP mRNA. Moreover, midbrain dopamine neurons express its preferred receptor GFRα4, allowing a cis type of action of PSP on dopamine neurons. Primary culture studies showed that PSP is as potent and efficacious as GDNF at promoting both survival and neuritogenesis of midbrain dopamine neurons. To study the function and therapeutic potential of PSP in vivo we engineered NSCs to overexpress PSP. PSP-c17.2 cells were found to stably express PSP mRNA and protein for at least 3 months in vivo, to disperse within the striatum, and to give rise to neurons, astrocytes, and a large proportion of oligodendrocytes that integrated within white matter tracts in the striatum. Moreover, PSP-c17.2 cells enhanced dopamine-dependent behavioral parameters in unlesioned mice and prevented the loss of dopamine neurons and the behavioral impairment of mice receiving intrastriatal 6-OHDA injections. Thus, our findings are consistent with a direct action of PSP on developing and adult midbrain dopamine neurons and suggest that the delivery of PSP by NSCs may constitute a very useful strategy in the treatment of Parkinson's disease.
AB - Persephin (PSP) is a neurotrophic factor of the GDNF family that has been found to promote the survival of multiple populations of neurons. In the present study we have examined: (1) the mechanism of action and the function of PSP on nigrostriatal dopamine neurons and (2) the therapeutic potential of PSP, delivered by neural stem cells (NSCs) in a model of Parkinson's disease. Interestingly we found that the prenatal ventral mesencephalon and the newborn striatum express high levels of PSP mRNA. Moreover, midbrain dopamine neurons express its preferred receptor GFRα4, allowing a cis type of action of PSP on dopamine neurons. Primary culture studies showed that PSP is as potent and efficacious as GDNF at promoting both survival and neuritogenesis of midbrain dopamine neurons. To study the function and therapeutic potential of PSP in vivo we engineered NSCs to overexpress PSP. PSP-c17.2 cells were found to stably express PSP mRNA and protein for at least 3 months in vivo, to disperse within the striatum, and to give rise to neurons, astrocytes, and a large proportion of oligodendrocytes that integrated within white matter tracts in the striatum. Moreover, PSP-c17.2 cells enhanced dopamine-dependent behavioral parameters in unlesioned mice and prevented the loss of dopamine neurons and the behavioral impairment of mice receiving intrastriatal 6-OHDA injections. Thus, our findings are consistent with a direct action of PSP on developing and adult midbrain dopamine neurons and suggest that the delivery of PSP by NSCs may constitute a very useful strategy in the treatment of Parkinson's disease.
UR - http://www.scopus.com/inward/record.url?scp=0036432028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036432028&partnerID=8YFLogxK
U2 - 10.1006/mcne.2002.1171
DO - 10.1006/mcne.2002.1171
M3 - Article
C2 - 12401443
SN - 1044-7431
VL - 21
SP - 205
EP - 222
JO - Molecular and Cellular Neuroscience
JF - Molecular and Cellular Neuroscience
IS - 2
ER -